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UGT1A1 genotype does not
affect tyrosine kinase
inhibitors efficacy and safety
in chronic myeloid leukemia
To the Editor:
Gilbert's syndrome (GS) is a condition characterized by intermittent
unconjugated hyperbilirubinemia without structural liver damage,
affecting about 10% of the caucasian population. It is an autosomal
recessive disorder, mainly associated with variations in uridine-
50-diphosphate (UDP)-glucuronosyltransferase gene (UGT1A1). In Cau-
casians, the most common variation is the TATA box polymorphism, in
which an insertion of an additional TA-repeat into the promoter region
of the gene results in a A(TA) 7TAA sequence, that differs from the more
prevalent A(TA) 6TAA. Gilbert's syndrome is a benign condition which
does not lead to liver inflammation, cellular destruction, fibrosis, or cir-
rhosis but is merely clinically characterized by intermittent episodes of
uncomplicated unconjugated hyperbilirubinemia.1
The effect of GS on liver complication and outcome of hematolog-
ical malignancies has been scarcely investigated, with only a previous
study in a series of children diagnosed with acute lymphoblastic
leukemia,2 a series of adult patients with Hodgkin lymphoma3 and
some anecdotal case reports in acute leukemia patients.4
Tyrosine-kinase inhibitors (TKIs) are currently used for the treat-
ment of chronic myeloid leukemia (CML). Nilotinib inhibits bilirubin
metabolism via UGT1A1, thereby increasing bilirubin levels; not sur-
prisingly, GS has been associated with nilotinib-induced hyper-
bilirubinemia in patients affected by CML.5-7 Similar increases in
bilirubin were also reported in patients with GS treated with imatinib
or dasatinib.8
The aim of the present study is to assess if in CML-chronic phase
(CML-CP) patients treated with either first- or second-generation
TKIs, GS has an impact on clinical outcomes, assessed by
cytogenetic/molecular response rates and progression-free survival
(PFS), as well as on hematological or extra-hematological toxicities.
We retrospectively collected data on CML-CP patients consecu-
tively treated with TKIs at our institution between February 2002 and
November 2018. All the following data were collected at baseline
before TKI initiation: sociodemographic and hematological variables,
disease risk scores (Sokal, Eutos, Hasford, and ELTS), and TKI starting
dose. Monitoring and responses evaluation followed the current
European LeukemiaNet recommendations.9 Progression-free survival
was calculated from the start of first-line TKI to any of the following
events: primary or secondary resistance, and/or discontinuation due
to intolerance. Hematological and extra-hematological toxicities were
graded according to the Common Toxicity Criteria - Adverse Events
(CTCAE) version 5.0.
Gilbert's syndrome genotype was investigated by polymerase chain
reaction (PCR) amplification of a region encompassing the TATA-box of
the UGT1A1 gene (forward primer: 5’-GTC ACG TGA CAC AGT CAA
AC-30: reverse primer: 50-TTT GCT CCT GCC AGA GGT-30; annealing
temperature: 62°C. RefSeq UGT1A1 NG_033238.1). DNA fragment
length analysiswas performed by 12%polyacrylamide gel electrophoresis
(PAGE): a 98 bp fragment indicating the presence of the (TA)6TAA wild-
type allele, while a 100 bp fragment accounts for the (TA)7TAA allele
(c.-41_-40dupTA). The more rare (TA)8TAA allele (c.-43_-40dupTATA)
could be as well evidenced by this technique as a 102 bp PCR product,
but it was not detected in any of the patient studied.
Clinical and sociodemographic characteristics were described
using absolute and relative frequencies. We evaluated time to resis-
tance (truncated at 10 years) according to GS genotype by calculating
the Kaplan-Meier function and by fitting univariate and multivariable
Cox models adjusted for gender, age, and line of therapy. P values
were obtained from post-estimation global Wald tests. Statistical anal-
ysis was performed with Stata 15 (StataCorp. 2017).
One hundred and five CML-CP patients consecutively treated
with either first- or second-generation TKIs were evaluated. Clinical-
demographic data at diagnosis are showed in Table S1. In particular,
concomitant drugs were reported in 49 patients (46.7%), with seven
patients taking more than five medications. Gilbert's syndrome geno-
types were distributed as follows: 17 (16.2%) patients were 7/7,
44 (41.9%) 6/7 and the remaining cases were wild-type.
The majority of the patients were treated with imatinib (69.5%),
following by nilotinib (17.1%) and dasatinib (13.3%). Complete cytoge-
netic response (CCyR) was obtained in 79 (75.2%) patients, of whom
55 (52.4%) were within 3 months of treatment. Among 7/7, 6/7 and
6/6 genotypes, CCyR was achieved by 12 (70.6%), 31 (70.4%) and
29 (65.9%) patients, respectively. Major molecular response (MMR)
was obtained in 73 patients (69.5%); among them eight (47%) were
7/7, 23 (52.3%) 6/7 and 20 (45.4%) 6/6. Deep molecular response
(DMR) was achieved in 51 (48.6%) patients, of whom 8 (47.1%),
23 (52.3%) and 20 (45.4%) showed a 7/7, 6/7, or 6/6 genotype,
respectively. Interestingly, none of these differences was statistically
significant.
Forty-seven patients switched to second-line therapy, of whom
18 (38.3%) for primary resistance, 14 (29.8%) for secondary resistance
and 15 (14.3%) for intolerance or unacceptable toxicity.
Among patients who experienced primary resistance, two (22.2%)
were 7/7, seven (36.8%) were 6/7 and nine (45%) wild-type. A similar
distribution was also recorded among patients who switched for
toxicity.
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Progression-free survival did not differ according to GS genotype
either in the univariate (P = .98) or in the adjusted Cox analysis
(P = .77) subgroups (Figure 1). Between second-line treated patients,
35 (74.5%) achieved an MMR and 17 (36.2%) a DMR. In this subset of
patients, no differences were observed between GS genotypes and
second-line MMR and/or DMR achievement.
Ten patients (9.5%) were in the third-line of treatment, mainly for
secondary resistance; among them, two (20%), four (40%) and four
(40%) were 7/7, 6/7 and 7/7, respectively.
Hematological toxicity was reported in 26 (24.8%) patients and
extra-hematological toxicities in 64 (61%) (Table S2). Hyper-
bilirubinemia was reported in 26 (40.6%) patients, of whom nine
(34.6%) reached grade 3/4. Among the latter, 55.6% of the cases
belonged to the homozygous genotype subgroup. However, no signif-
icant difference in hematological as well as extra-hematological toxic-
ity was found according to GS genotype (Table S2).
Hyperbilirubinemia is the most frequent laboratory adverse event
observed with nilotinib, but in most cases does not represent a true
hepato-cellular toxicity.10 Nilotinib and to a lesser extent other TKIs
have the potential to inhibit UGT1A1, which may contribute to TKI-
related unconjugated hyperbilirubinemia.
Gilbert's syndrome is often underestimated in clinical practice,
mainly because the specific laboratory text is performed only when
bilirubin levels are significantly increased. However, this condition can
be present also in patients with normal or borderline bilirubin levels.
In our case series GS was detected in a higher percentage of
patients than expected (about 16.2% with homozygous genotype vs
10% in the general population).
Even though homozygous patients showed a higher rate of grade
3/4 hyperbilirubinemia, GS did not affect response rate and outcome
in CML patients. This datum was further confirmed with all the three
TKIs used in first-line, that is, imatinib, dasatinib, and nilotinib. Indeed,
comparing patients with or without GS, no difference was observed in
terms of achievement of CCyR, MMR, DMR, hematological or extra-
hematological toxicity, regardless of the specific TKI used.
In conclusion, considering the concomitant occurrence of other
non-TKI-related causes of bilirubin increase, GS should not represent
an absolute contraindication to nilotinib therapy, as TKIs choice
should be based on other concomitant variables.
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Isolated isochromosomes i(X)
(p10) and idic(X)(q13) are
associated with myeloid
malignancies and dysplastic
features
To the Editor:
An isodicentric X chromosome, with a breakpoint in Xq13 named
idic(X)(q13), is a rare but recurrent abnormality found in about 1% of
myelodysplastic syndromes (MDS), especially in old females. Most
cases with idic(X)(q13) are MDS, but a number of acute myeloid leuke-
mias (AML), usually secondary to MDS, have also been reported, and
a few cases of myeloproliferative neoplasms (MPN).1 The idic(X)(q13)
is frequently the only cytogenetic abnormality, albeit one or more
copies of the idic, beside a normal X chromosome being present in the
same cells. This suggests that idic(X)(q13) may be implicated in the
early process of the disease. The presence of idic(X)(q13) is specifically
associated with MDS in the WHO classification. Its clonal detection
by conventional cytogenetics is sufficient to diagnose MDS, in case of
cytopenias without morphological dysplasia.2 Conversely, the isochro-
mosome of the short arm of chromosome X named i(X)(p10) is a very
rare abnormality. It is observed in some cases of myeloid or lymphoid
malignancies, both as a unique abnormality, and as part of a more
complex karyotype, in female, and less frequently in male patients.
Myelodysplastic syndromes evolution is heterogeneous with trans-
formation to AML in about 30% of cases. An International Prognostic
Scoring System (IPSS) is commonly used to predict leukemic evolution
of primary untreated adults and to adapt therapy. Revised (R) in 2012,3
this score includes bone marrow blast percentage, hemoglobin level,
absolute neutrophil count, platelet count and cytogenetics. There is no
definite prognostic impact from Idic(X)(q13), and is considered as
another abnormality in the intermediate group of the IPSS-R.
Recently, exome and genome-wide sequencing of MDS cases rev-
ealed a great diversity of genomic aberrations, with more than
25 recurrent mutations.4 Several genes involved in pre-messenger
RNA splicing have been shown to be mutated in half of MDS patients,
revealing a new leukemic pathway involving spliceosome dysfunction.
To characterize the clinical and genetic profile of myeloid neo-
plasms associated with idic(X)(q13) and i(X)(p10), we performed a retro-
spective study, between 2002 and 2017, of 45 patients with myeloid
neoplasm who presented these abnormalities. All patients gave their
informed consent in agreement with the Helsinki declaration; and the
Institutional Ethics Committee at Avicenne Hospital approved this
study. The Idic(X)(q13) chromosome was found in 33 cases, and the i(X)
(p10) in 12 patients who were all female. Ten cases were associated
with other chromosomal abnormalities mainly involving chromosomes
five and seven. The analysis was then restricted to 35 patients with an
isolated X chromosome abnormality. In the majority of cases (n = 29),
the X chromosome abnormality was detected at diagnosis. Isochromo-
somes could result from transverse, instead of longitudinal misdivision
of the centromere; another mechanism could be chromatid exchange
involving two homologous chromosomes. In both scenarios, it leads to
the loss of the long arm and gain of the short arm of chromosome X,
resulting in a state of genetic imbalance. It is possible that the fre-
quency of i(X)(p10) was previously underestimated in the literature.
The cytogenetic distinction between del(Xq) and i(Xp) is difficult due to
the similarity of Xp- and q-arm banding patterns, extending from the
centromere to band Xq24 (Figure 1).
A morphological centralized review of the bone marrow smear
was performed by two cytologists. The revised diagnosis was MDS
(n = 25) [MDS with ring sideroblasts (n = 1), MDS with uni (n = 1) or
multilineage dysplasia (n = 10) and with ring sideroblasts (n = 2), MDS
with excess blasts −1 (n = 6), MDS with excess blasts 2 (n = 3), MDS
with myelofibrosis (n = 2)] or AML with multilineage dysplasia (n = 2),
chronic myelomonocytic leukemia (n = 4), atypical chronic leukemia
(n = 1) or unclassifiable cytopenia (n = 3). The majority of patients
presented marked dysplastic features (>10%) in one or more of the
major lineages. No specific feature was observed.
Some patients had a history of previous neoplasia or myeloid neo-
plasm, including four solid tumors (breast cancer n = 3), two AML with
normal karyotype and NPM1 mutation, one acute lymphoblastic leukemia,
one lymphoma, one chronic myelocytic leukemia on complete remission,
two immune thrombocytopenias and two monoclonal gammopathies.
Nineteen analyzed patients presented a median of 2.9 mutations
in the 27 genes analyzed by Next Generation Sequencing. The most
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